Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies

Leukemia

Volumn 28, Issue 2, 2014, Pages 444-447

  Lemaire, M ^a   D'Huyvetter, M ^a,b   Lahoutte, T ^a,c   Van Valckenborgh, E ^a   Menu, E ^a   De Bruyne, E ^a   Kronenberger, P ^d   Wernery, U ^e   Muyldermans, S ^a,f   Devoogdt, N ^a   Vanderkerken, K ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b BELGIAN NUCLEAR RESEARCH CENTRE   (Belgium)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^d Erasmushogeschool Brussel   (Belgium)

^e CENTRAL VETERINARY RESEARCH LABORATORY   (United Arab Emirates)

^f DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; DISEASE MODELS, ANIMAL; HUMANS; MICE; MULTIPLE MYELOMA; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; SINGLE-DOMAIN ANTIBODIES; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; X-RAY MICROTOMOGRAPHY;

EID: 84893762476     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.292     Document Type: Letter

References (15)

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
2. Hamers-Casterman C, Atarhouch T,Muyldermans S, Robinson G, Hamers C, Songa EB et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363: 446-448.
3. Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther 2005; 5: 111-124.
4. Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 2004; 64: 2853-2857.
5. De Vos J, Devoogdt N, Lahoutte T, Muyldermans S. Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target. Expert Opin Biol Ther 2013; 13: 1149-1160.
6. Schoonooghe S, Laoui D, Van Ginderachter JA, Devoogdt N, Lahoutte T, De Baetselier P et al. Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer. Immunobiology 2012; 217: 1266-1272.
7. Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, King P et al. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. Leukemia 2009; 23: 1894-1903.
8. D'Huyvetter M, Aerts A, Xavier C, Vaneycken I, Devoogdt N, Gijs M et al. Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. Contrast Media Mol Imaging 2012; 7: 254-264.
9. Ma D, McDevitt MR, Barendswaard E, Lai L, Curcio MJ, Pellegrini V et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia 2002; 16: 60-66.
10. Put S, Schoonooghe S, Devoogdt N, Schurgers E, Avau A, Mitera T et al. SPECT imaging of joint inflammation with nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis. J Nucl Med 2013; 54: 807-814.
11. Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J 2000; 1: 351-356.
12. Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 2004; 18: 139-145.
13. Moshitzky S, Kukulansky T, Haimovich J, Hollander N. Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin. Immunol Cell Biol 2008; 86: 261-267.
14. Rousseau C, Ferrer L, Supiot S, Bardies M, Davodeau F, Faivre-Chauvet A et al. Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. Tumour Biol 2012; 33: 679-688.
15. Dolloff NG, Talamo G. Targeted therapy of multiple myeloma. Adv Exp Med Biol 2013; 779: 197-221.